GHK-Cu: what the copper peptide evidence actually shows

Key takeaways

• GHK-Cu's evidence splits hard by route. It has a decent topical and cosmetic record and almost no human data for the injected form that recovery vendors sell. The strongest human-relevant result is topical: applied to human skin in the lab, the copper tripeptide crossed into the tissue, about 136 micrograms of copper per square centimeter over 48 hours with about 82 held as a depot .
• The human wound evidence is topical and mixed. A 1994 randomized, vehicle-controlled trial of a topical GHK-Cu gel sped diabetic foot-ulcer closure (98.5 percent vs 60.8 percent area closure) , while a 2006 controlled study found no erythema benefit after laser resurfacing . Both used the gel on skin.
• The only registered mid-stage human trial is a topical gel. NCT07437586 is a Phase 2, vehicle-controlled study of 0.1 percent GHK-Cu gel on standardized skin wounds in 60 healthy adults, still recruiting with no results posted .
• Much of the hair-growth reputation is borrowed from a different molecule. The most-cited hair-follicle study tested AHK-Cu (alanyl-histidyl-lysine copper), a separate copper peptide from GHK-Cu .
• GHK-Cu carries copper, which the body tightly regulates. Copper is about a sixth of the complex by mass, the adult requirement is 0.9 mg per day and the oral upper limit is 10 mg per day, and injection bypasses the gut that normally controls copper absorption .
• The chemistry: GHK is a natural human tripeptide, glycyl-L-histidyl-L-lysine (PubChem CID 73587), and GHK-Cu is its copper(II) complex, the blue-green ingredient sold in cosmetics as Copper tripeptide-1 .

Skip to:

• Where the evidence is real, and where it is borrowed
• What GHK-Cu is: a copper-carrying tripeptide
• The mechanism story comes mostly from its discoverer
• The topical case: skin penetration and wound healing
• The hair claims mostly belong to a different peptide
• The injectable case barely exists
• The copper you are actually dosing
• Regulatory and sport status
• How to read a GHK-Cu claim

Where the evidence is real, and where it is borrowed

GHK-Cu is a real human peptide with a decent topical and cosmetic record, and an injectable use case that is running well ahead of its data. The route is the whole question. If you want the plain-language on-ramp first, the GHK-Cu beginner guide covers what it is and how people use it. This piece is the evidence, graded.

What GHK-Cu is: a copper-carrying tripeptide

GHK is a tiny peptide, just three amino acids: glycine, histidine, and lysine (glycyl-L-histidyl-L-lysine, PubChem CID 73587, molecular weight 340.4) . The histidine gives it a strong grip on copper, so in the body and in a serum it grabs a single copper(II) ion and becomes the blue-green complex GHK-Cu. Loren Pickart isolated GHK from human plasma in the 1970s, and it turns up in plasma, saliva, and urine .

GHK-Cu was also developed as an actual drug, prezatide copper (PubChem lists GHK-Cu under that name, CID 71587328, molecular weight 402.9), and tested topically as a wound gel sold under the name Iamin . It never became an approved drug, which is part of why it now lives in serums and research vials rather than on a pharmacy shelf.

Two facts about GHK matter for reading the rest of the evidence. First, it is genuinely native to the body, which is part of why it has a long cosmetic safety history at low concentrations. Second, the reviews report that GHK levels in plasma decline with age . The decline is real in the literature; the leap from there to any anti-aging claim for an injected dose is not.

The mechanism story comes mostly from its discoverer

The mechanistic case for GHK-Cu is broad and, on paper, impressive. The 2018 review by Pickart and Margolina reports that GHK stimulates collagen, elastin, and glycosaminoglycan synthesis, drives blood-vessel and nerve outgrowth, acts as an anti-inflammatory, suppresses NF-kappaB, and supports DNA repair, across skin, lung, bone, liver, and stomach tissue . The 2015 review goes further, describing GHK as capable of up- and down-regulating at least 4,000 human genes .

Read those numbers with the byline in mind. Both reviews are authored by researchers tied to the company that commercialized the ingredient, so they are the mechanistic and marketing rationale, not independent confirmation . A molecule that plausibly touches thousands of genes in a dish is interesting biology. It is not the same as a controlled trial showing that a given dose, by a given route, does a specific useful thing in a person. Keep the mechanism and the clinical proof in separate columns.

The topical case: skin penetration and wound healing

The best human-relevant GHK-Cu result is a skin-penetration study, and it is topical. Hostynek, Dreher, and Maibach applied the copper tripeptide to excised human skin and measured how much copper crossed and how much stayed. About 136 micrograms of copper per square centimeter permeated over 48 hours, and about 82 micrograms per square centimeter were retained in the tissue as a depot . That establishes the thing topical serums need it to do: applied to skin, GHK-Cu delivers copper into and through the tissue. It says nothing about injecting it.

The human wound evidence is real, but it is old and topical. In 1994 a multicenter, randomized, evaluator-blinded, placebo-controlled trial tested a topical GHK-Cu gel (sold then as Iamin) on diabetic neuropathic foot ulcers and beat vehicle clearly: 98.5 percent median area closure versus 60.8 percent, with closure about three times faster than vehicle and standard care . That is a genuine positive human result on the skin. A 2006 controlled study of topical GHK-Cu after CO2 laser resurfacing pointed the other way, finding no significant difference in how fast redness resolved, though the 13 people who finished rated their overall skin quality higher . Both trials used the gel on skin, and neither tested an injection.

The animal data points the same direction. In a mouse scald model, GHK-Cu packaged in liposomes shortened wound-healing time to 14 days and raised angiogenesis and cell-proliferation markers (CD31 and Ki67) versus untreated wounds . That is encouraging, and once again it was applied to the skin.

The hair claims mostly belong to a different peptide

Copper peptides get paired with minoxidil or finasteride for hair loss, as a serum or a scalp microinjection. When those hair claims cite a study, the study is frequently the wrong molecule. The most-cited hair-follicle result, Pyo and colleagues in 2007, tested AHK-Cu (alanyl-histidyl-lysine copper) and found it stimulated human hair-follicle elongation ex vivo and dermal-papilla-cell proliferation at very low concentrations . That is a real finding for AHK-Cu, and AHK-Cu is a different peptide.

GHK-Cu may well do something at the follicle too, and the general dermal-fibroblast and vascular-growth mechanisms in the review literature are plausible groundwork . Still, the strongest specific hair-follicle data on record is for a different copper peptide, so a claim that transplants it onto GHK-Cu has quietly switched molecules. Dedicated, adequately powered human hair-growth trials of GHK-Cu itself are what is missing.

The injectable case barely exists

Almost everything above is topical or ex vivo or animal. The recovery use that research-peptide vendors sell, subcutaneous GHK-Cu for tendons, joints, and general repair, sits on the thinnest evidence of any use. There is no completed or registered controlled human trial of injected GHK-Cu; the one registered Phase 2 study is topical . The recovery case is built by taking topical skin data, mouse wound data, and broad mechanism reviews and assuming they carry over to a needle. They might carry over, but nobody has shown it.

This is the core route mismatch, and it is where GHK-Cu marketing outruns GHK-Cu science. Skin-penetration numbers tell you what happens across skin, not what a systemic dose does to a joint. A mouse scald healing faster under a topical liposome gel does not validate a human injecting the same peptide for a shoulder. If you are going to use the injected form, use it knowing that part of the map is blank, not shaded in.

The copper you are actually dosing

GHK-Cu is a copper delivery system: a dose in milligrams of the peptide is also a dose of copper. Copper is roughly a sixth of the complex by mass: copper's atomic weight is about 63.5 and the whole GHK-Cu complex is about 403, so copper is near 16 percent of it. A 2 mg dose of GHK-Cu therefore carries roughly 0.3 mg of elemental copper. That is a rough figure from the molecular weights, not a safety threshold, but it puts the exposure in context.

For scale: the adult copper requirement is 0.9 mg per day, and the tolerable upper intake level for adults is 10 mg per day . A single topical or injected GHK-Cu dose is well under that ceiling on paper. Two things complicate the comfort. The upper limit is set for oral intake, where the gut regulates how much copper the body actually absorbs; an injection bypasses that control entirely, and there is no established safe injectable copper dose to compare against. And copper is cumulative: chronic excess is linked to liver damage and gastrointestinal symptoms, and the body has no fast route to dump a surplus .

One practical tell sits in the vial itself. GHK-Cu is oxidation- and light-sensitive, which is why serums ship in opaque or airless packaging. A product that has turned brown or thrown a precipitate has degraded. For the reconstitution math on an injectable vial, the peptide reconstitution calculator does the concentration arithmetic; get that wrong and every dose after it is wrong too.

Regulatory and sport status

GHK-Cu lives a double regulatory life that tracks its two routes. As a cosmetic ingredient under the name Copper tripeptide-1, it is sold worldwide in serums and creams; cosmetics and their ingredients other than color additives do not need FDA approval before going on the market . As an injectable it is not an FDA-approved drug, and a peptide compounded into an injectable falls under FDA's section 503A framework, which governs which bulk drug substances a pharmacy may compound with . The molecule is the same; the regulatory posture turns on how you use it.

For anti-doping, GHK-Cu is not named by name on the WADA 2026 Prohibited List the way BPC-157 (listed under S0) and thymosin beta-4 derivatives like TB-500 (listed under S2) are . That is not the same as cleared. The list carries broad catch-all language, and an athlete injecting a blended or research-grade vial cannot be sure of the contents, so a tested athlete should confirm current status with their anti-doping authority rather than assume a cosmetic peptide is safe to inject.

How to read a GHK-Cu claim

Most GHK-Cu guides open with a benefit and a dose chart, then backfill the science with whatever study is handy. The map above gives you a faster filter. Before you accept a GHK-Cu claim, run it through five questions.

1. Which route did the cited study use? Topical or ex-vivo skin data does not validate an injection, and a mouse wound model does not validate a human joint.
2. Which molecule did it test? If the study is Pyo 2007 or another hair-follicle result, check whether it used AHK-Cu rather than GHK-Cu .
3. Who wrote it? Much of the mechanism literature is from the ingredient's developer; useful for hypotheses, weak as independent proof .
4. Is it a finished human trial, a lab dish, or a plan? GHK-Cu's finished human wins are topical, and the only currently registered trial is a topical gel still recruiting, with no results .
5. Does the claim account for the copper? A dose in milligrams of GHK-Cu is also a dose of copper, and copper accumulates .

Those five checks sort most GHK-Cu claims quickly, because almost every inflated one fails on route, molecule, or author. For the popular GHK-Cu plus BPC-157 plus TB-500 blend, the GLOW stack write-up walks through the combined evidence, and spotting high-quality peptides covers the vial-quality problem under any injectable.

Where that leaves GHK-Cu

The practical move with GHK-Cu is to weight its topical evidence and discount its injectable evidence, because that is how the data splits. A serum has a real cosmetic and wound-healing record behind it. A research vial for recovery is running almost entirely on extrapolation, and anyone injecting it should at least know that is what they are buying.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 15 entries, primary canon (PubChem, PubMed, ClinicalTrials.gov, NIH ODS, MedlinePlus, FDA, WADA), last reviewed 2026-07-18.

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.